🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Hepatobiliary Disease

Prospective Cohort and Biobank of Patients With Nonalcoholic Fatty Liver Disease NCT07051863n/a1 site📍 Lugano Fondazione Epatocentro Ticino Effects of TOTUM-448 on Liver Fat Content, Cardiometabolic Risk Factors and Gut Microbiota Among Participants with MASLD NCT06704321NA1 site📍 Québec Valbiotis · Tests: TOTUM-448, Placebo A Study of TSRA-196 in Adults With PiZZ Alpha-1 Antitrypsin Deficiency (AATD) NCT07227207Phase 1, Phase 28 sites📍 Jacksonville📍 Boston📍 Rochester Tessera Therapeutics, Inc. · Tests: TSRA-196 NAFLD Clinical Care Pathway NCT06671886NA1 site📍 Houston VA Office of Research and Development · Tests: E-trigger The COherence of Scatter Identification and Exclusion Algorithm Study NCT06975579n/a1 site📍 London Institute of Cancer Research, United Kingdom · Tests: Ultrasound image processing Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States NCT05832229Phase 213 sites📍 La Jolla📍 Los Angeles📍 Los Angeles National Institute of Diabetes and Digestive and Kidney Dis… · Tests: Rosuvastatin Study on the Quantitative Assessment of the Risk of Hepatocellular Carcinoma in Patients With Chronic Liver Disease Using Multi-parameter Magnetic Resonance Imaging NCT06060769n/a1 site📍 Zhuhai Fifth Affiliated Hospital, Sun Yat-Sen University An Observational Study Evaluating Patients With Chronic Liver Diseases Associated With Hepatic Steatosis NCT05335603n/a1 site📍 Hvidovre University of Copenhagen Efficacy and Safety of Recombinant Human FGF21-Fc Fusion Protein for Injection (TQA2225/AP025) in Adult Subjects With Non-alcoholic Steatohepatitis (NASH) NCT06569524Phase 253 sites📍 Lu'an📍 Lu'an📍 Beijing Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Phar… · Tests: TQA2225/AP025 or TQA2225/AP025 Placebo 25mg, TQA2225/AP025 or TQA2225/AP025 Placebo 50mg Diet and Meal Timing in Patients With Metabolic Dysfunction Associated Steatoic Liver Disease NCT05332613NA1 site📍 New York Weill Medical College of Cornell University · Tests: TRE plus SOC, SOC, TRE Fructose and Liver Diseases in Youth: Help Them FLY NCT05528471NA1 site📍 Edmonton University of Alberta · Tests: Dietary intervention Health Literacy and Self-efficacy Expectations in Patients With Alcohol-related Liver Cirrhosis NCT07169526n/a1 site📍 Hanover Hannover Medical School SASL Swiss Cirrhosis Cohort NCT06092385n/a10 sites📍 Lugano📍 Basel📍 Bern University Hospital, Basel, Switzerland · Tests: Data collection High-resolution PET-CT Specimen Imaging for the Perioperative Visualization of Resection Margins NCT06835426NA1 site📍 Ghent Algemeen Ziekenhuis Maria Middelares · Tests: Single intravenous injection of the radiotracer, Imaging resected specimen using the high-resolution PET-CT specimen im… Investigating Pathological Mechanisms in Non-alcoholic Fatty Liver Disease NCT04141592n/a1 site📍 London Queen Mary University of London · Tests: Bariatric Surgery Androgens and NAFLD Longitudinal Cohort Study NCT06124261n/a2 sites📍 San Francisco📍 Durham University of California, San Francisco Metabolic Features Effects on FAST Score in MASLD Patients NCT06867419n/a1 site📍 Tanta Tanta University · Tests: Transient Elastography Prognostic Significance of Fatty Liver Disease in Bariatric Patients NCT03535142NA1 site📍 Esbjerg Esbjerg Hospital - University Hospital of Southern Denmark · Tests: Bariatric surgery 2D-shear Wave Spleen Elastography in Clinically Significant Portal Hypertension and High-risk Varices NCT07122622n/a1 site📍 Roma Fondazione Policlinico Universitario Agostino Gemelli IRCCS EUS-guided Portal Pressure Gradient (PPG) Measurement: a Potential Alternative to the Traditional HVPG NCT06863012NA1 site📍 Barcelona Fundacio Privada Mon Clinic Barcelona · Tests: Endoscopic Ultrasound-Guided Portal Pressure Gradient (EUS-PPG) Measurement, Hepatic Venous Pressure Gradient (HVPG) Me… Increased Risk of Non-alcoholic Fatty Liver Disease in Low Birth Weight Individuals NCT05890365n/a1 site📍 Herlev Steno Diabetes Center Copenhagen Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Disease NCT05045482Phase 11 site📍 Indianapolis Zydus Therapeutics Inc. · Tests: Saroglitazar Magnesium 1 mg, Saroglitazar Magnesium 2 mg A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH NCT06419374Phase 3330 sites📍 Birmingham📍 Homewood📍 Chandler Hoffmann-La Roche · Tests: Pegozafermin, Placebo Pyramidal Versus Continuous Training Effects on Fatty Liver NCT06803108NA1 site📍 Giza Cairo University · Tests: pyramidal activity program, aerobic activity program Effect of Erugliflozin On Liver Fat, Liver Fibrosis and Glycemic Control in Type II DM Patients With NASH/NAFLD NCT05644717Phase 41 site📍 Peshawar Getz Pharma · Tests: Ertugliflozin 5 mg, 15mg Longitudinal Observational Study Of Chinese With NAFLD/NASH NCT03151473n/a1 site📍 Hong Kong Humanity and Health Research Centre Digoxin In NASH (CODIN) NCT06588699Phase 22 sites📍 New Haven📍 New Haven Yale University · Tests: Digoxin, Placebo Veteran-Centered Care for Advanced Liver Disease (Vet-CALD) NCT06068491NA8 sites📍 Little Rock📍 Long Beach📍 Palo Alto VA Office of Research and Development · Tests: Vet-CALD Pathogenesis of Pediatric Nonalcoholic Fatty Liver Disease (NAFLD) NCT04634643n/a1 site📍 New Haven Yale University · Tests: Usual diet and physical activity Strategic Treatment Reduction in Very Early Liver Disease With 4 Weeks Sofosbuvir Plus Glecepravir-pibrentasvir NCT03855917Phase 43 sites📍 Darlinghurst📍 Sydney📍 Adelaide Kirby Institute · Tests: Sofosbuvir 400mg [Sovaldi], Glecaprevir/pibrentasvir (300mg/120mg)
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy